FDA grants 510(k) clearance to AngioDynamics' AlphaVac F1885 System for pulmonary embolism. Expanded indication broadens treatment options. Sales slightly below consensus, but pro forma basis sees growth.
AngioDynamics resolves decade-long patent litigation with Becton, Dickinson in landmark settlement, streamlining legal expenses and marking a significant milestone for the company.
Portfolio optimization enhances strategic focus and follows initiative to restructure manufacturing footprintCompany to discontinue sales of radiofrequency ablation and Syntrax productsAngioDynamics, Inc. (NASDAQ:ANGO),
225-cm Catheter Length Expands Access Points in Atherectomy Procedures to Help Reduce Access Site Complications and Accelerate Patient RecoveryAngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
AngioDynamics Inc (NASDAQ: ANGO) has reported a second-quarter (Q2) FY24 adjusted EPS loss of $(0.05), compared to the consensus of $(0.07) and EPS income of